NCT04546399 | AALL1821 | COG-AYA

Clinical Trial: NCT04546399 | AALL1821 | COG-AYA

NCT Number: NCT04546399

Protocol ID: AALL1821

Sponsor: COG-AYA

Disease Site: Leukemia-Acute Lymphocytic Leukemia (ALL)

Disease Category: Leukemia

Detail: A Phase 2 Study of Blinatumomab (NSC# 765986) in Combination with Nivolumab (NSC # 748726), a Checkpoint Inhibitor of PD-1, in B-ALL Patients Aged >/= 1 to < 31 Years Old with First Relapse

For more details, click here.

Interested in participating in this trial?

Clinical Trial

First Name

Last Name

Phone

Preferred Contact Method:

Preferred Location:

Patient Type:

Current Patient New Patient

Interested in:

Cancer Clinical Trial Blood Disorder Clinical Trial

Disease Site:

Disease Category

What do all the numbers mean on clinical trials?

National Clinical Trial Identifier

The National Clinical Trial (NTC) is assigned by the National Library of Medicine when a new study appears in the clinical trials database.

ex: NCT0526225 | GY026 | NRG

PROTOCOL IDENTIFICATION NUMBER

Any unique identifier assigned to the protocol by the sponsor.

ex: NCT0526225 | GY026 | NRG

STUDY SPONSOR

A sponsor is an individual, institution, company or organization that takes the responsibility to initiate, manage and/or finance the clinical trial.

ex: NCT0526225 | GY026 | NRG